Drug Profile
Borofalan (10B) - Stella Pharma
Alternative Names: Borofalan - Stella Pharma; SPM-011; SteboronineLatest Information Update: 13 Feb 2023
Price :
$50
*
At a glance
- Originator Stella Pharma
- Developer Osaka University; Stella Pharma; Sumitomo Heavy Industries
- Class Amines; Antineoplastics; Borates; Propionic acids; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Head and neck cancer
- Phase II Glioma; Haemangiosarcoma
- Phase I Malignant melanoma
Most Recent Events
- 13 Feb 2023 Borofalan (10B) is still in phase I trials for Malignant melanoma (In the elderly, In adults) in Japan (IV) (NCT04293289) (JapicCTI195062)
- 31 Dec 2022 Stella Pharma completes a phase I trial in Malignant melanoma and Haemangiosarcoma (In adults, In the elderly) in Japan (IV) (NCT04293289) (JapicCTI195062)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Malignant-melanoma(In the elderly, In adults) in Japan (IV)